Dr. Bruce Carleton, PharmD, is director of the Pharmaceutical Outcomes Programme (POPi) at BC Children's Hospital, a program devoted to evaluating the impact of drug therapy on patients' health outcomes, and chair of the Division of Translational Therapeutics in the Department of Pediatrics, Faculty of Medicine, University of British Columbia. He is a professor at the University of British Columbia in the Department of Pediatrics, the Department of Medical Genetics, the School of Public and Population Health, the Centre for Health Services and Policy Research, and the Faculty of Pharmaceutical Sciences, and an adjunct professor in the School of Health Information Science at the University of Victoria. Dr. Carleton is a senior clinician scientist at the BC Children's Hospital Research Institute and runs the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), a Canadian and international network devoted to the study of the human genome to understand the biological mechanisms of drug and vaccine outcomes, particularly serious adverse events. This research is used for the development of innovative risk prediction tests, experimental therapeutic protective strategies as well as new drugs that are safer and more effective. He is also clinical pharmacology lead of the MedSafe Clinics at British Columbia Children's and St. Paul's Hospitals in Vancouver, which are devoted to characterizing serious adverse drug reactions and defining culprit drugs so that patients and health care providers have clear messages about what drugs are safe and can be used in the future. This clinic uses a variety of clinical, genomic and cell-based tools. Dr. Carleton also serves the US Government as a special government employee to advise the Advisory Committee for Pharmaceuticals and Clinical Pharmacology of the Food and Drug Administration (FDA). He is a fellow of the American College of Clinical Pharmacology and the International Society of Pharmacoepidemiology.